<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01422200</url>
  </required_header>
  <id_info>
    <org_study_id>2010-2319</org_study_id>
    <nct_id>NCT01422200</nct_id>
  </id_info>
  <brief_title>Flu Vaccine Study in Neuromuscular Patients 2011</brief_title>
  <official_title>Comparison of the Immunogenicity of Intramuscular Versus Subcutaneous Administration of Trivalent Inactivated Influenza Vaccine in Individuals With Neuromuscular Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the immune response of two different injection methods&#xD;
      (Intramuscular V.S. Subcutaneous) of the 2011-2012 seasonal Influenza (Flu) vaccine among&#xD;
      patients with neuromuscular conditions who have significant muscle degeneration. This&#xD;
      research study hypothesizes that the subcutaneous route of vaccine administration, as&#xD;
      compared to the intramuscular route, may confer at least comparable, or possibly better,&#xD;
      immunogenicity. At least 30 individuals followed by the CCHMC Neuromuscular Comprehensive&#xD;
      Care Center will be recruited to participate in this study lasting approximately one to two&#xD;
      months with two clinic visits and one follow-up telephone call. Immunogenicity will be&#xD;
      assessed by comparing hemagglutination inhibition (HI) antibody titers obtained pre- and&#xD;
      post-vaccination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals with neuromuscular diseases are more prone to influenza-related morbidity.&#xD;
      Vaccination is the most effective measure to reduce the influenza disease burden. In the&#xD;
      United States, the recommended route of administration for the inactivated influenza vaccine&#xD;
      is intramuscular. In other countries, the subcutaneous, deep subcutaneous, and intramuscular&#xD;
      routes are all considered acceptable for influenza vaccine administration. The United States&#xD;
      CDC states that subcutaneous influenza vaccine doses, provided they are age-appropriate, may&#xD;
      be counted as valid.&#xD;
&#xD;
      Those with neuromuscular diseases have muscle fibrosis that may potentially make&#xD;
      intramuscular vaccines more effective. Those with Duchenne muscular dystrophy receive&#xD;
      systemic corticosteroids to reduce inflammation. Corticosteroids may suppress antibody&#xD;
      responses to vaccines. The goal of this research study is to evaluate the immunogenicity and&#xD;
      safety of intramuscular and subcutaneous administration of inactivated influenza vaccine in&#xD;
      individuals with neuromuscular diseases. This is a single site, open-label, randomized study.&#xD;
      At the first visit, a blood sample was collected prior to vaccination. Each subject received&#xD;
      either an intramuscular or subcutaneous vaccine administered in the anterolateral aspect of&#xD;
      the thigh. Within 30 minutes of vaccination, subjects rated pain at the injection site using&#xD;
      a numeric pain scale (0-10). Subjects and their caregivers were also asked to record local&#xD;
      and systemic adverse events on diary sheets from day 0 to day 4 after vaccination. Subjects&#xD;
      were instructed to notify the study staff by telephone should they develop any serious&#xD;
      adverse reactions following vaccination. At a second study visit approximately 28 days later,&#xD;
      a repeat blood sample was obtained. The blood samples obtained pre-vaccination and also at&#xD;
      day 28 were tested for hemagglutination inhibition (HI) titers to the three influenza vaccine&#xD;
      strains. rovider's office. The geometric mean titer ratios for each of the three vaccine&#xD;
      strains were calculated as the ratios of postvaccination to prevaccination titers at&#xD;
      geometric mean scale.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Participant, care provider, and investigator are not masked. The outcomes assessor (personnel determining the HI titers) is masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titer Ratio for Each Vaccine Strain</measure>
    <time_frame>immediately before vaccination and 21-28 days after vaccination</time_frame>
    <description>Serum HI antibody titers for each vaccine strain immediately prior to study vaccine receipt and 21-28 days after study vaccine receipt</description>
  </primary_outcome>
  <other_outcome>
    <measure>Safety: Summary of Local and Systemic Reactogenicity Symptoms</measure>
    <time_frame>4 days following receipt of study vaccine</time_frame>
    <description>For the 4 days following receipt of study vaccine (days 0 to 4), the following local reactions will be assessed: pain, redness, and swelling. The following systemic reactions will also be assessed: body ache, weakness, irritability, headache, and cough.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <condition>Spinal Muscular Atrophy</condition>
  <condition>Congenital Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Subcutaneous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mL of Fluzone (2011-2012 Northern Hemisphere formulation) influenza vaccine administered via subcutaneous route once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intramuscular</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5 mL of Fluzone (2011-2012 Northern Hemisphere formulation) influenza vaccine administered via intramuscular route once</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2011-2012 seasonal flu vaccine Subcutaneous</intervention_name>
    <arm_group_label>Subcutaneous</arm_group_label>
    <other_name>fluzone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2011-2012 seasonal flu vaccine Intramuscular</intervention_name>
    <arm_group_label>Intramuscular</arm_group_label>
    <other_name>fluzone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-ambulatory;&#xD;
&#xD;
          -  Quadriceps muscle strength of MRC (Medical Research Council Scale) grade 3 or below&#xD;
&#xD;
          -  Any subject who is between 3 to 8 years of age must have received at least two doses&#xD;
             of influenza vaccine last season or at least one dose tow or more years ago.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject must not have a history of severe reactions following previous immunization&#xD;
             with influenza vaccine.&#xD;
&#xD;
          -  Subject must not have previously received a 2011-2012 influenza vaccine.&#xD;
&#xD;
          -  Subject must not have a history of Guillain-Barre syndrome.&#xD;
&#xD;
          -  Subject must not have received a live viral vaccine (i.e., MMR, varicella) within 28&#xD;
             days prior to receipt of the study vaccine.&#xD;
&#xD;
          -  Subject must not have any condition that the investigator believes would render&#xD;
             vaccination unsafe or interfere with successful completion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brenda Wong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 22, 2011</study_first_submitted>
  <study_first_submitted_qc>August 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2011</study_first_posted>
  <results_first_submitted>August 18, 2020</results_first_submitted>
  <results_first_submitted_qc>October 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 19, 2020</results_first_posted>
  <last_update_submitted>October 14, 2020</last_update_submitted>
  <last_update_submitted_qc>October 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DMD</keyword>
  <keyword>SMA</keyword>
  <keyword>CMD</keyword>
  <keyword>flu vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Subcutaneous</title>
          <description>2011-2012 Northern Hemisphere formulation trivalent inactivated influenza vaccine</description>
        </group>
        <group group_id="P2">
          <title>Intramuscular</title>
          <description>2011-2012 Northern Hemisphere formulation trivalent inactivated influenza vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subcutaneous</title>
          <description>2011-2012 Northern Hemisphere formulation inactivated influenza vaccine</description>
        </group>
        <group group_id="B2">
          <title>Intramuscular</title>
          <description>2011-2012 Northern Hemisphere formulation inactivated influenza vaccine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>10-28 years range</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.20" spread="4.88"/>
                    <measurement group_id="B2" value="19.37" spread="4.23"/>
                    <measurement group_id="B3" value="18.78" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer Ratio for Each Vaccine Strain</title>
        <description>Serum HI antibody titers for each vaccine strain immediately prior to study vaccine receipt and 21-28 days after study vaccine receipt</description>
        <time_frame>immediately before vaccination and 21-28 days after vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous</title>
            <description>Subjects receiving 2011-2012 Northern Hemisphere trivalent inactivated influenza vaccine by subcutaneous route</description>
          </group>
          <group group_id="O2">
            <title>Intramuscular</title>
            <description>Subjects receiving 2011-2012 Northern Hemisphere trivalent inactivated influenza vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer Ratio for Each Vaccine Strain</title>
          <description>Serum HI antibody titers for each vaccine strain immediately prior to study vaccine receipt and 21-28 days after study vaccine receipt</description>
          <units>geometric mean titer ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HINI vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.76" lower_limit="2.31" upper_limit="6.11"/>
                    <measurement group_id="O2" value="3.53" lower_limit="1.43" upper_limit="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1.49" upper_limit="2.68"/>
                    <measurement group_id="O2" value="1.46" lower_limit="0.94" upper_limit="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B vaccine strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" lower_limit="1.24" upper_limit="2.5"/>
                    <measurement group_id="O2" value="2" lower_limit="1.11" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Safety: Summary of Local and Systemic Reactogenicity Symptoms</title>
        <description>For the 4 days following receipt of study vaccine (days 0 to 4), the following local reactions will be assessed: pain, redness, and swelling. The following systemic reactions will also be assessed: body ache, weakness, irritability, headache, and cough.</description>
        <time_frame>4 days following receipt of study vaccine</time_frame>
        <population>Subjects who completed the diary sheets</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous</title>
            <description>0.5 mL of Fluzone (2011-2012 Northern Hemisphere formulation) influenza vaccine administered via subcutaneous route once&#xD;
2011-2012 seasonal flu vaccine: Subcutaneous flu vaccine</description>
          </group>
          <group group_id="O2">
            <title>Intramuscular</title>
            <description>0.5 mL of Fluzone (2011-2012 Northern Hemisphere formulation) influenza vaccine administered via intramuscular route once&#xD;
2011-2012 seasonal flu vaccine: Intramuscular flu vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Summary of Local and Systemic Reactogenicity Symptoms</title>
          <description>For the 4 days following receipt of study vaccine (days 0 to 4), the following local reactions will be assessed: pain, redness, and swelling. The following systemic reactions will also be assessed: body ache, weakness, irritability, headache, and cough.</description>
          <population>Subjects who completed the diary sheets</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body ache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weakness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritabiltity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Local and systemic adverse events were collected on diary sheets from day 0 to day 4 after vaccination. Serious adverse events were collected through the final study visit, about 28 days.</time_frame>
      <desc>Within 30 minutes of vaccination, subjects rated the painfulness using a picture or numeric pain scale. Subjects and their caregivers were also asked to record local and systemic adverse events on diary sheets from day 0 to day 4 after vaccination. A mild symptom is one which is easily tolerated, a moderate symptom causes interference with usual daily activities, and a severe symptom results in the inability to perform daily activities.</desc>
      <group_list>
        <group group_id="E1">
          <title>Intramuscular</title>
          <description>2011-2012 Northern Hemisphere formulation trivalent inactivated influenza vaccine administered once intramuscularly</description>
        </group>
        <group group_id="E2">
          <title>Subcutaneous</title>
          <description>2011-2012 Northern Hemisphere formulation trivalent inactivated influenza vaccine administered once via subcutaneous route</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Body Ache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Paine/tenderness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size as a pilot study</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Brenda Wong</name_or_title>
      <organization>Cincinnati Children's Hospital Medical Center</organization>
      <phone>5136364222</phone>
      <email>brenda.wong@cchmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

